J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e c h a n i s m o f a c t i o n
2 S e e a l s o
3 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
P r o S a v i n
A d d l a n g u a g e s
A d d l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
It is manufactured by Oxford BioMedica . Results from a Phase I/II clinical trial were published in the Lancet[2] [3] [4]
Mechanism of action [ edit ]
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase , tyrosine hydroxylase and GTP-cyclohydrolase 1 , to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[5] [6]
See also [ edit ]
References [ edit ]
^ Palfi, Stéphane; Gurruchaga, Jean Marc; Ralph, G. Scott; Lepetit, Helene; Lavisse, Sonia; Buttery, Philip C.; Watts, Colin; Miskin, James; Kelleher, Michelle; Deeley, Sarah; Iwamuro, Hirokazu (2014-03-29). "Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial" . The Lancet . 383 (9923): 1138–1146. doi :10.1016/S0140-6736(13 )61939-X . ISSN 0140-6736 . PMID 24412048 . S2CID 4993549 .
^ Communications, Maggie Kuhl Director Research & CEO (28 January 2014). "ProSavin Trial Results: Once Again, a Gene Therapy Approach to Parkinson's Yields Encouraging Safety Data but Modest Efficacy | Parkinson's Disease" . www.michaeljfox.org . Retrieved 2021-04-09 .
^ Wexler, Marisa (20 August 2019). "Parkinson's Gene Therapy in Clinical Trial, AXO-Lenti-PD, Safe And Effective in Monkey Model of Disease, Study Says" . Retrieved 2021-04-09 .
^ "Positive results in Phase I/II trial" . OxfordBiomedica. 19 November 2008.
^ "Prosavin" . OxfordBiomedica. Archived from the original on 16 March 2014.
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=ProSavin&oldid=1220786163 " C a t e g o r i e s : ● D r u g s a c t i n g o n t h e n e r v o u s s y s t e m ● V i r o t h e r a p y ● P h a r m a c o l o g y s t u b s H i d d e n c a t e g o r i e s : ● O r p h a n e d a r t i c l e s f r o m J a n u a r y 2 0 2 2 ● A l l o r p h a n e d a r t i c l e s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 2 5 A p r i l 2 0 2 4 , a t 2 2 : 0 8 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
